DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/kt2zpx/basal_cell) has announced the addition of the "Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- 4SC AG
- Biofrontera AG
- Biogenomics Limited
- Biosceptre International Limited
- Bristol-Myers Squibb Company
- Genextra S.p.a.
- MediGene AG
- Novartis AG
- Oncovir, Inc.
- Redx Pharma Ltd
- Transgene SA
- aminolevulinic acid hydrochloride
- interferon alfa-2b (recombinant)
- Oshadi D + Oshadi R
- Small Molecule to Inhibit Smoothened Receptor for Basal Cell Carcinoma
- Small Molecules to Inhibit Casein Kinase 1 for Cancer
For more information visit http://www.researchandmarkets.com/research/kt2zpx/basal_cell